Advanced approaches to stem cell-based therapies is necessary for myocardial regenerative therapy because treatments have yielded modest results in the clinic. Our group previously demonstrated genetic modification of cardiac stem cells with Pim-1 kinase overexpression rejuvenated aged cells and potentiated myocardial repair. Despite these encouraging findings, concerns were raised regarding oncogenic risk associated with Pim-1 kinase overexpression. Testing of these c-kit+ cardiac interstitial cells (cCICs), derived from heart failure patient samples, overexpressing Pim-1 (cCICs-Pim-1) for indices of oncogenic risk was assessed by soft agar colony formation, micronucleation, gamma-Histone 2AX foci, and transcriptome profiling. Collectively, findings demonstrate comparable phenotypic and biological properties of cCICsPim-1 compared to baseline control cCICs with no evidence for oncogenic phenotype. Using a highly-selective and continuous sensor for quantitative assessment of PIM1 kinase activity, a 7-fold increase in cCICs-Pim-1 versus cCICs resulted. Kinase activity was elevated in IKKs, AKT/SGK, CDK1-3, p38, and ERK1/2 in addition to Pim-1, correlating Pim-1 overexpression to contribute to Pim-1-mediated effects. Enhancement of cellular survival, proliferation, and other beneficial properties to augment stem cell-mediated repair without oncogenic risk is a feasible, logical, and safe approach to improve efficacy and overcome current limitations inherent to cellular adoptive transfer therapeutic interventions.
Introduction
Stem cell-based therapeutic approaches are poised to revolutionize treatment of numerous diseases previously considered untreatable [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] , but further improvements and enhanced products are needed to make this therapy truly safe and efficacious.
Longstanding challenges of poor survival for adoptively transferred cells and low engraftment rates have stymied progress toward enhancing efficacy, especially in the area of myocardial regenerative medicine. [11] [12] [13] [14] [15] [16] [17] Our group has pioneered use of genetic engineering to enhance regenerative potential of human c-kit+ Cardiac Interstitial Cells (cCICs), historically referred to as cardiac stem/progenitor cells (CPCs), intended for autologous therapeutic utilization. cCICs support myocardial repair and improve cardiac performance through reduction of scar size and increased cardiac output. 18 Pim-1, an endogenous constitutively activated enzyme found within cCICs, is produced in response to stress or pathologic injury in the myocardium. 19 Pim-1 up-regulation enhances cell survival through mediating transcription, cell growth, proliferation, survival, and expansion of cCICs 20, 21 . Our previous efforts with over a decade of research on Pim-1 biology demonstrates remarkable regenerative effects mediated by adoptively transferred human Pim-1 enhanced CPCs in rodent and swine models with significantly improved cardiac performance relative to unmodified CPCs, bone marrow stem cells and mesenchymal stem cells. [22] [23] [24] Human Pim-1 enhancement of CPCs also exhibits reversal of aging affects, such as down regulation of senescence markers, increased telomere length and mitochondrial activity and the augmented proliferation. 25 The technology of using autologous Pim-1 enhanced cCICs (cCICs-Pim-1), patented as CardioEnhancersä, represents convergent evolution of extensive high-level mechanistic biological research that creates a novel and efficacious treatment for heart failure. 26 However, association of Pim-1 as a marker of oncogenic potential [27] [28] [29] has raised some concerns regarding the potential for transgene-mediated overexpression of Pim-1 to promote increased oncogenic risk using cCICs-Pim-1. 30 Furthermore, concerns continue to persist regarding insertional mutagenesis through use of lentiviral vectors for genetic modification that could promote oncogenic transformation. [31] [32] [33] [34] [35] Establishing the safety profile of cCICs-Pim-1 regarding oncogenic risk is a recurring recommendation to advance implementation, forming the rationale for studies performed in this report.
Pim-1 protein is an evolutionarily highly conserved serine / threonine kinase unique by virtue of constitutive activation, meaning that rather than having to be 'activated' as with most kinases, it is active in nascent translated form. 36 Thus, Pim-1 activity is regulated by concerted control of gene transcription, mRNA translation, and protein degradation. The target phosphorylation consensus sequence for Pim-1 is found in proteins mediating transcription, cell growth, proliferation, and survival. 37, 38 Transgenic mouse experiments [39] [40] [41] and cell culture experiments [42] [43] [44] [45] demonstrate PIM-1 exerts potent synergistic activity with c-MYC, p21Cip1/WAF1, STAT3, JNK, and survivin, as well as with other proteins particularly when the protein function involves proliferation and cell survival. However, it is very important to recognize that PIM-1 is considered a weak oncogene at best because it is not a transforming factor by itself and this assessment has not significantly changed over the years. Murine myeloid cells in culture are dependent upon IL-3 and rapidly die if the IL-3 was withdrawn, suggesting a major function of Pim-1 is to act as a survival factor.
Further support of this notion comes from the observation that forced expression of PIM-1 improves factor-dependent cells survival in the absence of IL-3 46 . Pim-1's role in cell survival led to the discovery that it down regulates activity of the ASK1 proapoptotic pathway. 47 In general, Pim-1 upregulation enhances cell survival whereas loss of Pim-1 increases apoptotic cell death. Protective effects of Pim-1 depend upon kinase activity as borne out by experiments using a dominant-negative kinase dead mutant construct. 46, 48 In fact, Pim-1 transgenic overexpression in lymphoid tissue showed "Eµ-pim-1 mice lack sufficient sensitivity to justify their routine use in short-term carcinogenicity testing in general." Despite increased predisposition to tumor induction in the lymphoid compartment, Pim-1 overexpression did not increase susceptibility to oncogenic induction by genotoxic carcinogens. 49 Protein kinases linked to cancer development may share phosphorylation consensus sequences with Pim-1, but their modes of regulation are dissimilar, their expression patterns differ, and separate signal transduction pathways activate them. The collective complexities of Pim-1 biology, lentiviral genetic engineering, and uncertainties regarding oncogenic risk justified a thorough and comprehensive study to profile the effect of Pim-1 overexpression in human cCICs.
Materials and Methods
Cell Culture. K562 cells, a human bone marrow lymphoblast cell line derived from a female patient with chronic myelogenous leukemia (CML), were obtained from ATCC ® (CCL-243 ™ ).
Human cCICs cell lines for individual isolates from three patients undergoing surgical implantation of a left ventricular assist device (LVAD) were used for characterizations.
cCICs were isolated and expanded as previously described 50 and each was subjected to lentiviral modification to express Pim-1 GFP in a bicistronic construct or GFP alone as a control cell line. Culture media formulations used for cell culture and assays are presented in Supplemental Table 1 . Cell pellets (~1 x 10 6 cells washed with 1x PBS) were prepared and snap frozen in liquid nitrogen (or dry ice) and stored at -80 o C for up to 3 months before use as described below. Lentiviral Infection. Lentiviral preparations were created as previously described 23, 24 with modifications as detailed in Supplemental Methods section. Early passage (4-5) cCICs were plated over night at density of 50,000 cells/well on a 6-well plate. The following day cells were washed with 1xPBS prior to adding 1mL of cCICs medium (Supplemental Table   2 ). Lentivirus infection was performed at a multiplicity of infection ratio of 3 particles per cell, with virus added per well (PIM1 L1701 titer 2.6 x 10 8 TU/mL; GFP L1702 titer 1.8 x 10 8 TU/mL) in 1mL of warm cell culture medium. The plate was intermediately shaken throughout the day. At the end of the day, another mL of warm cell culture medium was added. The next morning the virus removed, cells were washed with PBS and replenished with cell culture medium. 2 days after infection cells were divided into two T25 flasks. 2 days after the division, one of the flasks was continued for expansion and the other one was used for FACS and protein quantification.
Immunoblotting. Cells were plated 24-hours prior to lysis (50,000 cells/well 6-well plate).
On the day of collection, cells were washed with cold 1xPBS, placed on ice and lysed with 50µL of sample buffer with protease and phosphatase inhibitors (added immediately before use), followed by boiling for 5 minutes and sonication. Lysates were cleared by centrifugation before loading on to 4%-12% NuPage Novex Bis Tris gel (Invitrogen), transferred on to a polyvinylidene fluoride (PVDF) membrane and blocked for an hour at room temperature in 5% skim milk, 1x tris-buffered saline tween-20 (TBST). Primary antibodies were incubated over night at 4°C. PIM-1 (Thermo, ZP003) 1:1,000; GFP (Rockland, 600-101-215) 1:500; GAPDH (Sicgen, AB0067-200) 1:1,000 in 5% skim milk.
Membranes were washed with TBST 3x5 minutes. Secondary antibodies (Licor, 1:2,000) were incubated for an hour at RT, followed by 3x5 minutes TBST wash. Membranes were imaged on Licor Odyssey CLx.
Immunocytochemistry. Next day after plating 40,000 cells/well in a glass bottom chamber slide were fixed in 4% formaldehyde (Thermo, 28908) for 5 minutes, rinsed with 1xPBS 3x5 minutes. Cells were permeabilized with 0.1M Glycine for 5 minutes followed by 0.1% Triton-x100 treatment for 10 minutes at RT. Followed by 3x5 minute wash in Table 1 ) with a 1x final concentration was plated on 6-well plates (1mL/well) in sterile conditions. The agar was allowed to solidify under laminar flow for at least 30 minutes. Meanwhile, the cells were lifted, counted and a cell suspension of 6,667 cells/mL was prepared in 2x cell culture medium. Cells were mixed 1:1 with 0.6% noble agar solution at 42°C to avoid immature solidification of agar.
1.5mL of cell solution (5,000 cells/well) in agar was plated on top of 0.5% agar base. The cell and agar mixture solidified after 30 minutes under a laminar flow hood prior to placing into a cell culture incubator. To maintain sufficient humidity and nutrition levels in the wells, 100µL of cell culture medium was added twice a week. After 14 days 200µL of nitroblue tetrazolium (Invitrogen, N6495) was added to the wells and incubated overnight in a cell culture incubator. The following day the wells were scanned using Licor Odyssey CLx and the colonies were counted using ImageJ software. A more detailed protocol has previously been published 1 .
In Vitro Micronucleus Assay. On the first day 50,000 cCICs were plated per well on a 6-well plate. The following day, the cells were washed with 1mL of 1xPBS prior to adding Crude Lysate Preparation. Cells pellets stored at -80 o C were thawed on ice prior to resuspending in Cell Extraction Buffer (CEB) containing 50 mM TRIS, pH 7.5, 150 mM NaCl, 2 mM EGTA, 30 mM NaF, 10 mM Na4P2O7, 100 µM Na3VO4, 1% Triton X-100, 50 mM β-glycerophosphate, 1 mM DTT, Sigma Protease Inhibitor cocktail (#P8340) 10%;
Sigma Phosphatase Inhibitor cocktail (#P285) 10%. Specifically, cell pellets from His067/P-12/PIM-1 or His067/P-12/GFP control conditions (1x10 6 cells) were solubilized in 0.6 ml CEB and sonicated on ice for 2 seconds X10 with 5 seconds cooling in between sonication. Clear cell lysate was obtained after centrifuging @6000g for 10 minutes @ 4 C. Control samples of K562 cells, which are known to exhibit Pim-1 kinase activity, were generated as described above to serve as positive controls for the assay. The Bradford method was used to determine the total protein concentration of clear cell lysate, which was ~ 1 mg/mL for all three samples. Once generated, crude cell lysate samples were kept on ice and immediately assayed for kinase activity using a panel of CSx-Substrates as described below. 
Results

Lentiviral engineering of human cCICs for stable overexpression of Pim-1 kinase.
Cell lines derived from three individual heart failure patient samples (see Table 1 ) were identified as Line #1 (H15-096), Line #2 (H13-067), or Line #3 (H16-107). The cCIC lines expanded from each patient sample were genetically engineered using lentiviral vectors expressing either GFP alone or GFP and Pim-1 in a bicistronic construct. Efficiency of genetic modification of patient cell lines was assessed by flow cytometric analyses ( Figure   1A ). GFP expression alone in stably modified cCICs was 78.5%, 88.5%, and 80.2% for Lines 1, 2, and 3, respectively. Similar efficiency of GFP expression in cCICs-Pim-1 for expression of GFP / Pim-1 was observed at 81.7%, 84.7%, and 80.9% for Lines 1, 2, and 3, respectively. Protein expression of GFP as well as Pim-1 in cell lysates from each line was confirmed by immunoblot analysis (Figure 1B) , with an average significant increase of Pim-1 kinase expression in engineered lines of 25-fold increase in GFP / Pim-1 cCICs relative to corresponding cells expressing GFP alone ( Figure 1C ). These results demonstrate the efficient and consistent genetic modification of human cCICs to overexpress Pim-1 at levels significantly higher than normally found in these cells.
Soft agar colony growth is not induced in Pim-1 overexpressing cCICs.
Anchorageindependent growth in soft agar is a well described assay for oncogenic transformation of cells. 59, 60 Ability of cCICs to proliferate in soft agar was assessed for lines expressing GFP alone as well as GFP / Pim-1 (Figure 2) . The positive control cell line HEK293 demonstrated growth competency in the soft agar assay, forming colonies clearly visible within 2 weeks after plating (Supplemental Figure 1) . In contrast, cCICs lines were unable to form colonies in soft agar and were all scored as negative for growth at the two-week time point. All three cCIC lines showed comparable negative results, with representative images shown for Lines 1 and 3 (Figure 2 ). These results demonstrate that Pim-1 overexpression in cCICs fails to promote growth of the cells in soft agar consistent with normal, non-transformed cell phenotypic properties. 
Micronucleation is not increased in
Foci of g-H2AX immunolabeling are not increased in Pim-1 overexpressing cCICs.
DNA double-strand breaks and blocked replication forks are marked by phosphorylation of histone 2AX (H2AX) that accumulates at the site of damage and can be visualized as foci by immunocytochemistry. The three cCIC lines were prepared for immunofluorescence confocal microscopy and immunolabeled for γH2A.X (phospho-S139) with DAPI as a nuclear counterstain ( Figure 4A ). Control cells were lentivirally-modified Lines expressing GFP alone without Pim-1.
Presence of punctate nuclear-localized labeling characteristic of yH2AX (phospho-S139) immunolabeling indicative of genotoxic damage was quantitated using microscopic assessments of 50 cells per experimental group. Number of γH2A.X foci per nucleus were comparable between all Lines tested and no statistically significant difference was observed between Lines expressing GFP alone versus those expressing GFP / Pim-1 ( Figure 4B 
2-4). Correlation analysis of gene expression profiles demonstrated that transcriptional
profiles were not significantly altered between cCICs expressing GFP alone versus cell expressing GFP / Pim-1 (Fig. 5A ). Furthermore, transcriptional impact of Pim-1 overexpression is minimal compared to inherent patient transcriptional diversity (Fig. 5B) .
A total of 25 differentially expressed genes (DEGs) were detected with only 14 upregulated genes in Pim-1 overexpressing cCICs (Fig. 5C ). Individual and collective quantification of normalized transcripts and subsequent alignment to spliced isoforms was performed to confirm overexpression of Pim-1 variant 1 despite minimal differences in the global transcriptome ( Supplemental Figures 4 and 5 , confirmatory FASTA sequences of overexpressed splice form of PIM-1). Additionally, no significant differences were observed in the overall detected genes, genes displaying high abundance (FPKM>1), or the relationship between detected genes and DEGs (Fig. 5D and Supplemental Figure 6 ).
Collectively, these results confirm lack of significant transcriptional reprogramming pursuant to Pim-1 overexpression in cCICs.
Kinase profiling using real-time sensors reveals elevation of PIM-1 activity and multiple Pim-1 target pathways in cCICs.
Given the critical role of PIM-1 activity in conferring the beneficial properties of cCICs, we felt it was very important to measure PIM-1 activity directly. The Imperiali laboratory has pioneered the use chelation-enhanced fluorescence via optimized substrate sensors containing the unnatural fluorogenic aminoacid Sox. 52, [55] [56] [57] This one-step homogeneous assay format provides a direct, continuous (kinetic) and highly-quantitative measure of kinase activity that can be performed with purified enzyme or crude cell or tissue lysates. 53, 54, 58, 67 Using a highly-selective sensor for quantitative assessment of PIM1 kinase activity (Supplemental Figure 7) , we demonstrated a 7-fold increase in Pim-1 from cCICs-Pim-1 versus control cCICs ( Figure   6 ). We then used a panel of sensors designed for other kinases relevant to PIM-1 signaling and observed increases in lysates from cCICs versus control cCICs for CK1 (1.8-fold), IKK-family (2.7-fold), AKT/SGK (3.1-fold), CDK1-3/5 (3.7-fold), p38/MAPKs (2.8-fold) and ERK1/2 MAPKs (2.6-fold) ( Figure 7 and Table 2 ). In contrast, we saw no increase in activity with a sensor that measures the activity of JNK1, 2 or 3 (Figure 7 and Table 2 ).
These changes are consistent with heightened kinase activity resulting from Pim-1 overexpression, reported by the Sussman laboratory and others, that contributes to Pim-1-mediated effects. Importantly, these changes are all strikingly lower than the observed increase in PIM-1 activity, which presumably highlights an important balance in posttranscriptional and post-translational influences established in these cCICs that may help explain the beneficial effect of Pim-1 genetic engineering to enhance cell survival and proliferation, while avoiding any negative consequences, such as an oncogenesis. This conclusion is consistent with those previously proposed and reported by the Sussman laboratory. 20
Discussion
Next generation stem cell therapeutic approaches will require innovative solutions to current limitations in implementation. A universally accepted and serious challenge for efficacy is poor survival, engraftment, and persistence of adoptively transferred cells, which is poor in the setting of autologous treatment and arguably even worse in allogeneic therapy. Toward the goal of confronting these longstanding issues, our group embarked upon a molecular interventional strategy to enhance stem cell therapy through genetic engineering with pro-survival and pro-proliferative Pim-1 kinase. Myocardial Pim-1 biology as reported since 2007 spawned 64 peer review articles including 24 publications from the Sussman laboratory (PubMed key word search for "Pim-1" and "cardiac"). As such, the mechanism of Pim-1 action is likely documented equal to or better than any other cardiac regenerative therapy. Pim-1 expression is stimulated by a variety of hormones, cytokines and mitogens, many of which are associated with cardioprotective signaling [38, 39] . Despite pro-proliferative effects mediated by Pim-1, oncogenic transformation has never been observed in any of our samples, and all Pim-1 enhanced cCICs were amenable to differentiation in vitro that resulted in acquisition of post-mitotic characteristics when injected into rodents or swine. Histological evaluation findings for oncogenic transformation, tumorigenicity, teratomas, ectopic tissue formation or similar neoplastic plastic processes were all negative for all cCICs treated animals on whole body necropsy either at 4-or 8-weeks following study product administration. 22 Human cCICs overexpressing Pim-1 show no evidence of oncogenicity in NOD/SCID mice 23 . Data from this validation study revealed trafficking, distribution, and persistence of cCICs-Pim-1 for up to 32 weeks. Negligible risk from Pim-1 modification is further supported by the following findings: A) Pim-1 literature inhibiting activity in cancer reinforces Pim-1 function as a cell survival enhancer after undergoing an oncogenic event rather than an initiator of transformation. Likelihood for oncogenic transformation is very remote because of cell-type effects and context-dependent action. PIM-1 is a weak oncogene at best because it is not a transforming factor by itself as supported by published literature. 41, [68] [69] [70] B) High level Pim-1 overexpression in cCICs is cytotoxic rather than oncogenic and we are unable to expand cardiac interstitial cells exhibiting high Pim-1 overexpression. C) The CMV promoter employed in the lentiviral vector is progressively down-regulated in vivo, likely by epigenetic modification (e.g. methylation) such that Pim-1 levels in cCICs-Pim-1 is increasingly difficult to discriminate from endogenous myocardium within weeks after adoptive transfer. 22 Karyotype analysis demonstrated human cCICs-Pim-1 to be normal without chromosomal aberrations. 23 Multiple potential explanations likely account for lack of a metastatic phenotype for cCICs-Pim-1 that stands in contrast to unrelated observations pertinent to embryonic stem cells or iPS cells. Specifically, augmented regenerative potential means that cCICs-Pim-1 are delivered at lower cell dosing relative to alternative cell types, and cCICs-Pim-1 are predisposed to cardiogenic commitment as evident by transcriptional profiling as well as protein expression and therefore likely undergo apoptotic death by anoikis if lodged out of context in non-myocardial tissue. Nevertheless, despite this collective body of evidence concerns continue to be articulated that oncogenic risk resulting from Pim-1 overexpression is a potential issue. 30 There is no clear consensus for an optimal experimental model to definitely assess vector safety for a particular cell engineering application. Lentiviral vectors have integration sites away from transcriptional regulatory sites and low oncogenic risk and to quote: 75 , and inherited disorders affecting hematopoietic cells. 76 In addition, lentiviral vectors have integration sites away from transcriptional regulatory sites, making them a safe therapeutic option 33 . These findings are in stark contrast to published literature showing chromosomal abnormalities in certain embryonic stem cells and induced pluripotent stem cells where oncogenesis remains a significant barrier to therapeutic implementation. 77 Prior studies with hematopoietic stem cells that, unlike cCICs, normally undergo complex genetic rearrangements as part of their differentiation program exhibited tumorigenic potential from induction of cellular oncogenes adjacent to the integration site 33 .
Heart failure associated with aging has been proposed to be a "stem cell disease" characterized by impaired functional reserve of the endogenous stem cell pool due to exhaustion, senescence, depletion, or inability to cope with the environmental stressors. 78 Stem cell therapy for cardiac repair holds great promise, but the ability of cCICs to repair damaged myocardium declines with age. [78] [79] [80] Shortening of telomere length has been linked to both senescence 81 and cell death 82 , further highlighting concerns related to aging and pathological stress. cCICs derived from patients with advanced biological age and severe concurrent clinical features will require rejuvenation to reverse deleterious effects of aging and disease. Lack of overt risk of oncogenic transformation as well as the ex vivo approach to genetic modification described in this study that allows for rigorous screening prior to reintroduction into a patient for autologous therapy provides reassurance of safety for use of Pim-1 mediated enhancement for cCICs therapeutic use. 
Figure legends
